99. 慢性特発性偽性腸閉塞症 Chronic intestinal pseudo-obstruction Clinical trials / Disease details
臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04118699 (ClinicalTrials.gov)  | December 25, 2019 | 23/9/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial | Chronic Intestinal Pseudo-obstruction | Drug: Rifaximin oral tablet;Drug: Placebo oral tablet | Yokohama City University | ASKA Pharmaceutical Co., Ltd. | Active, not recruiting | 20 Years | 74 Years | All | 12 | Phase 2 | Japan | 
| 2 | JPRN-jRCT2031190137 | 25/12/2019 | 20/11/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Chronic Intestinal Pseudo-obstruction  CIPO, abdominal bloating  | Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks. | Ohkubo Hidenori | NULL | Not Recruiting | >= 20age old | < 75age old | Both | 12 | Phase 2 | Japan |